A Phase I dose-escalation study of afatinib combined with nintedanib in patients with advanced solid tumors.

Gordon, Michael S; Springett, Gregory M; Su, Yungpo Bernard; Ould-Kaci, Mahmoud; Wind, Sven; Zhao, Yihua; LoRusso, Patricia M

Gordon, Michael S; Springett, Gregory M; Su, Yungpo Bernard; Ould-Kaci, Mahmoud; Wind, Sven; Zhao, Yihua; LoRusso, Patricia M.

Affiliation

Gordon MS; Pinnacle Oncology Hematology, 9055 E Del Camino, Suite 100, Scottsdale, AZ 85258, USA.

Future Oncol ; 11(10): 1479-91, 2015.

Article in En | MEDLINE | ID: mdl-25963426

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Neoplasms/drug therapy; Neoplasms/pathology; Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Female; Humans; Indoles/administration & dosage; Indoles/pharmacokinetics; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors/administration & dosage; Protein Kinase Inhibitors/pharmacokinetics; Quinazolines/administration & dosage; Quinazolines/pharmacokinetics; Treatment Outcome

Key words

BIBF 1120; BIBW 2992; ErbB family blocker; Phase I; afatinib; nintedanib; pharmacokinetics; triple angiokinase inhibitor

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Neoplasms Type of study: Clinical_trials Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Future Oncol Year: 2015 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google